• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aldara (imiquimod)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aldara (imiquimod)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Aldara is indicated for treatment of external genital and perianal warts in adults. Aldara is a vanishing cream applied by the patient and will be available by prescription only.

    Clinical Results

    In a clinical trial with 209 patients, 50% (72% females, 33% males) had wart clearance with Aldara cream after 16 weeks of therapy compared to 11% of vehicle group. Of those who cleared, 72% (n=39/54) of patients from the Aldara group and 82% (n=9/11) of the vehicle group remained wart clear after 12 weeks of follow-up. Aldara cream was generally well-tolerated. Most patients experienced a variety of local skin reactions; most experienced redness (61%) and some experienced erosion (30%) and flaking (20%), but these tended to be mild to moderate in intensity. Only 4% of clinical trial patients reported pain and less than 2% discontinued due to skin reactions.

    Additional Information

    Genital warts is a sexually transmitted disease (STD) caused by the human papilloma virus (HPV). HPV is one of the most common - and least talked about - of all STDs; at least 10 to 20 percent of sexually active Americans are thought to be infected. Genital warts is growing at a rate of 750,000 new cases each year, is spread by sexual contact with an infected partner and is highly contagious. This life long virus can cause warts in the genital and perianal areas in females and males. Male sexual partners of infected women often have HPV penile infection.

    Genital warts may cause itching, burning, pain and tenderness. Although there is no cure for genital warts, treatment can alleviate physical symptoms and psychological reactions such as problems with sexuality, shame, embarrassment and self-blame.

    Approval Date: 1997-03-01
    Company Name: 3M Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing